This amendment directs the Department of Medical Assistance Services (DMAS) to evaluate pharmaceutical manufacturer programs and other contracting arrangements available to state Medicaid programs that are intended to reduce the costs of glucagon-like peptide-1 (GLP-1) receptor agonists and related therapies. DMAS must project cost savings for such programs or contracting arrangements and is authorized to implement the program or arrangement with the greatest projected savings to the Medicaid program.